What happened with the FDA and compounded GLP-1s, and who is still operating legally?

Short version

• In early–mid 2024 the FDA stepped up enforcement against pharmacies and telehealth firms that were compounding and marketing GLP‑1 products (semaglutide, tirzepatide, etc.) as mass‑market copies of brand drugs. The agency said many of those operations were violating the Federal Food, Drug, and Cosmetic Act because they were essentially making copies of FDA‑approved products and/or distributing them without patient‑specific prescriptions and proper oversight.
• That doesn’t mean all compounding stopped. FDA‑approved makers (e.g., Novo Nordisk and Eli Lilly) and pharmacies/clinics that follow FDA and state pharmacy rules are still operating legally. Compounding is still permitted in narrow, patient‑specific situations.

What the FDA objected to (brief)

• Making “essentially copies” of approved GLP‑1 drugs through compounding and selling them at scale.
• Marketing compounded GLP‑1s broadly for weight loss without an individualized prescription and clinical oversight.
• Potential safety/quality issues (sterility, dosing, labeling, supply chain) when products are made and distributed outside standard drug approval and manufacturing processes.

Legal framework (how compounding can be done legally)

• 503A compounding pharmacies: may legally compound only pursuant to a valid prescription for an identified patient. They cannot routinely mass‑produce copies of an FDA‑approved drug.
• 503B outsourcing facilities: can produce larger batches for hospitals/clinics but must register with the FDA and meet stricter requirements; they also cannot use compounding to circumvent the approval process for copies of marketed drugs except in limited circumstances.
• In short: compounding is legal when there is a documented medical need for an individualized product (e.g., a specific dose or formulation that an approved product doesn’t provide), but not as a substitute for available approved drugs for general sale.

Who is still operating legally

• Manufacturers of FDA‑approved GLP‑1 drugs: Novo Nordisk (Ozempic, Wegovy, Rybelsus) and Eli Lilly (Mounjaro, Zepbound) — their production/distribution of approved products is legal.
• Retail and specialty pharmacies that fill prescriptions for FDA‑approved GLP‑1s (CVS, Walgreens, Costco, Walmart, and specialty pharmacies like CVS Specialty, Accredo, Optum Specialty) — when they dispense an FDA‑approved product per a valid prescription.
• Clinicians and telehealth services that perform a genuine medical evaluation, issue patient‑specific prescriptions, and prescribe the FDA‑approved branded or generic GLP‑1s — these are legal.
• Compounding pharmacies that follow the rules: they may compound a GLP‑1 only when a licensed prescriber has a patient‑specific need that cannot be met by an approved product and when state and federal compounding rules are followed.

How you can tell if a provider is operating legally

• Do they require a real medical evaluation and a documented, patient‑specific prescription? If not, that’s a red flag.
• Are they advertising “generic” or “compounded” GLP‑1s as a cheaper mass‑market substitute for Ozempic/Wegovy/Mounjaro? That’s likely noncompliant.
• Is the pharmacy registered with your state board of pharmacy and (for outsourcing facilities) with the FDA? Check the state board or the FDA Warning Letters/Enforcement page.
• Are they filling the brand name product from a specialty/retail pharmacy or shipping vials/syringes without prescription documentation? The latter is risky and often unlawful.

If you want safe, legal access to GLP‑1 treatment

• See your primary care physician or an endocrinologist for evaluation and an appropriate prescription.
• Fill the prescription at a reputable retail or specialty pharmacy (CVS, Walgreens, Costco, Walmart, CVS Specialty, Accredo, Optum Specialty). These pharmacies handle storage, cold chain, and patient counseling.
• If cost is a concern, check manufacturer savings programs (Novo Nordisk and Eli Lilly have patient assistance/copay programs), GoodRx price checks, and your insurer’s specialty pharmacy options.
• If you’re considering a telehealth provider, use one that documents an appropriate virtual visit and prescribes brand or authorized generics (examples of mainstream telehealth platforms that provide prescription services include PlushCare and Amwell), and confirm they send prescriptions to recognized pharmacies or specialty pharmacies.

If you’re currently using compounded GLP‑1s

• Talk with your prescriber about the clinical rationale and whether switching to an FDA‑approved product is appropriate.
• If you suspect a provider is operating outside the law, you can report them to the FDA (MedWatch) and your state board of pharmacy.

If you want, tell me the name of the clinic or pharmacy you’re asking about and I can help check public FDA/state actions and explain whether their practices appear compliant.